Colorectal or bowel cancer is a cancer that begins in the large bowel and is the fourth most common cancer in the UK. Metastatic/advanced colorectal cancer, or Stage IV, occurs when the cancer has spread to another part of the body; this is most commonly to the liver. A small proportion of colorectal cancer cases develop due to deficiencies in a repair mechanism for DNA; this may contribute to an increase in potential faulty (mutated) DNA. A high rate of this mutation is known as high microsatellite instability or mismatch repair deficient. These subsets of patients may have outcomes which are worse than those observed in the overall metastatic colorectal cancer population.
The most common treatment options for advanced colorectal cancer in the UK is surgery, radiotherapy and chemotherapy. Pembrolizumab is a type of immunotherapy that is delivered intravenously by a drip and that works by targeting specific proteins that stimulate an immune response attacking the cancer cells. It increases the body’s natural ability to identify and kill cancer cells. If licenced, pembrolizumab will offer an additional first line treatment option for patients with advanced colorectal cancer and prolong the time without cancer progression and overall survival.
Pembrolizumab is a medicinal product that is being investigated as treatment for patients with relapsed or refractory classical Hodgkin lymphoma (cHL). Hodgkin lymphoma is a type
of cancer of the lymphatic system and it is the most common type. The condition is called relapsed or refractory when it recurs after a period of improvement or when it does not
respond to treatment. The most common symptom of Hodgkin lymphoma is a swelling in the neck, armpit or groin.